Henoch-Schönlein purpura
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
For patient information click here
Synonyms and keywords: Anaphylactoid purpura; purpura rheumatica; SchönleinâHenoch purpura
Overview
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
In medicine (rheumatology and pediatrics) Henoch-Schönlein purpura (HSP, also known as allergic purpura) is a systemic vasculitis (inflammation of blood vessels) characterized by deposition of immune complexes containing the antibody IgA, especially in the skin and kidney. It occurs mainly in children. Typical symptoms include palpable purpura (small hemorrhages in the skin), joint pains and abdominal pain. Most cases are self-limiting and require no treatment apart from symptom control, but the disease may relapse (in 33% of cases) and cause irreversible kidney damage (in 1%).[1]
Historical Perspective
The disease was named Henoch-Schonlein purpura (HSP) after Johann Schonlein and Eduard Henoch due to their role in establishing the clinical manifestations of the disease
Classification
Pathophysiology
Henoch-Schönlein purpura (HSP) is an immune complex-mediated disease with circulating immune complexes and IgA rheumatoid factors usually follows upper respiratory tract infections, various viruses, and the bacteria have been implicated as triggers of the disease.
Causes
The common causes of Henoch-Schönlein purpura (HSP) are infections, medications, hypersesitivity, vaccinations, genetics etc.
Differentiating Henoch-Schönlein Purpura from other Diseases
Henoch-Schönlein purpura should be differentiated from other immune complex mediated small vessel vasculitis such as Anti-glomerular basement membrane disease, Cryoglobulinemic vasculitis, Hepatitis C virus-associated cryoglobulinemic vasculitis, Hypocomplementemic urticarial vasculitis (anti-C1q vasculitis).
Epidemiology and Demographics
The incidence of HSP is approximately 6-20 cases per 100,000 individuals. The prevalence of HSP is more in children of 4-6 years age group. HSP usually affects Caucasians than any other ethnic groups. Males are more commonly affected by HSP than females. The Male to female ratio is approximately 1.5-2:1.
Risk Factors
Henoch-Schönlein purpura (HSP) is associated with following risk factors it’s most common in children of 2 to 6 years, involves young boys more than girls, Asian and white race, spring, fall and winter months, Group A streptococci, Mycoplasma, Epstein-Barr virus infections, and environmental exposure of allergens, organophosphates, cold temperature.
Screening
There is insufficient evidence to recommend routine screening for HSP.
Natural History, Complications and Prognosis
Henoch-Schönlein purpura is a self-limiting illness in the majority of patients but can rarely lead to complications such as proteinuria, End Stage Renal Disease, myocardial infarction, pulmonary hemorrhage, pleural effusion, intussusception, orchitis, GI bleeding, bowel infarction, seizures, neuropathies. The prognosis is usually good but rarely its worse in adults with renal involvement.
Diagnosis
Henoch-Schönlein purpura is diagnosed using a biopsy of the skin and kidney.
History and Symptoms
The signs and symptoms of Henoch-Schönlein purpura (HSP) are skin lesions such as palpable purpura, abdominal pain, melena, bloody diarrhea, hematemesis, duodenal ulcers, arthralgia.
Physical Examination
Physical examination of patients with HSP is usually remarkable for palpable purpura.
Laboratory Findings
There is no specific diagnostic test available for HSP. Platelet count, coagulation studies such as PT, aPTT, and BT are done to rule out other diseases like coagulopathies. They are usually normal. Urinalysis is done to check for any blood in the urine or proteinuria for renal involvement. Serum IgA levels are elevated in the majority of patients with HSP, and in patients with renal involvement higher IgA levels are detected.
Electrocardiogram
There are no ECG findings associated with Henoch-Schönlein purpura.
Chest X Ray
There are no x-ray findings associated with Henoch-Schönlein purpura (HSP).
CT
MRI
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Surgery
Surgical intervention is not recommended for the management of Henoch-Schönlein purpura.
Medical Therapy
Henoch-Schönlein Purpura (HSP) is usually treated with supportive management by adequate hydration, balancing fluid and electrolyte, and controlling hypertension. Symptoms such as arthritis, edema, fever are treated with acetaminophen, leg elevation, and adequate hydration. Pharmacological management includes use of analgesics, NSAIDs, corticosteriods and various other immuno-suppressants. Plasmapheresis may be effective in delaying the progression of kidney disease and is usually done in addition to steroids.
Primary Prevention
There are no established measures for the primary prevention of Henoch-Schönlein purpura.
Secondary Prevention
There are no established measures for the secondary prevention of Henoch-Schönlein purpura.
Cost-Effectiveness of Therapy
Future or Investigational Therapies
References
Historical perspective
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
The disease was named Henoch-Schonlein purpura (HSP) after Johann Schonlein and Eduard Henoch due to their role in establishing the clinical manifestations of the disease.
Historical perspective
- The historical perspective of Henoch-Schönlein purpura:[1]
- The first case of Henoch-Schönlein purpura was described by Herberden in the year 1801.
- He described a young boy with a skin rash, abdominal pain, hematuria, and subcutaneous edema.
- The disease was named Henoch-Schonlein purpura (HSP) after Johann Schonlein and Eduard Henoch due to their role in establishing the clinical manifestations of the disease.
- Johann Schonlein identified purpura and joint pain as symptoms of HSP, which at the time he referred to as purpura rheumatica.
- Eduard Henoch described the associated gastrointestinal and renal complications of the HSP.
References
Classification
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
There is no established system for the classification of Henoch-Schönlein purpura.
Classification
There is no established system for the classification of Henoch-Schönlein purpura.
References
Pathophysiology
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Henoch-Schönlein purpura (HSP) is an immune complex-mediated disease with circulating immune complexes and IgA rheumatoid factors usually follows upper respiratory tract infections, various viruses, and the bacteria have been implicated as triggers of the disease.
Pathophysiology
The pathophysiology of HSP:[1][2][3]
- HSP is a small vessel leukocytoclastic vasculitis, but its pathophysiology is not completely understood.
- In patients with HSP the serum IgA levels are elevated, HSP is an immune complex-mediated disease with circulating immune complexes and IgA rheumatoid factors usually follows upper respiratory tract infections, various viruses, and the bacteria have been implicated as triggers of the disease.
- Patients with HSP have circulating IgA immune-complexes, patients with HSPN have an additional large molecular mass IgA1–IgG-containing circulating immune complexes.
- The IgA1 molecule has a hinge region containing up to six O-linked glycan chains consisting of N-acetylgalactosamine, usually with an attached ÎČ1,3-linked galactose.
- It has been reported that in patients with HSP, the activity of ÎČ1,3-galactosyltransferase in peripheral B cells is reduced, leading to a lack of terminal ÎČ1,3-galactosyl residues in the hinge region of IgA1.
- The primary defect leading to the production of such abnormally glycosylated IgA1 is probably heritable.
- These aberrantly glycosylated IgA1 molecules have been shown to form immune complexes with IgG antibodies specific for galactose-deficient IgA1, thereby inhibiting the binding of the IgA molecules to hepatic receptors and avoiding their internalization and degradation by hepatic cells.
- This formation results in an increased amount of IgA immune complexes in circulation.
- The complexes may then deposit in renal mesangial areas and activate the complement system by the alternative or lectin pathways, which play a major role in the pathophysiology of this disease.
- Further, after depositing in the mesangium, the galactose-deficient IgA1 immune complexes activate mesangial cells.
- This results in the proliferation of cells such as macrophages and lymphocytes and the production of inflammatory and profibrogenic cytokines and chemokines, which play a pivotal role in mesangial cell proliferation, matrix expansion, and inflammatory cell recruitment.
- Other mechanisms for developing HSP
- Nephritis-associated plasmin receptor, a group A streptococcal antigen, has been reported in some cases of HSP.
- Activation of the eosinophils and expression of the alpha-smooth muscle actin in the kidney also play a vital role in the pathogenesis of Henoch-Schönlein purpura.
Pathology
- Indications
- No rash
- Abnormal renal function tests
Skin biopsy
- Light Microscopy
- IgA deposition in postcapillary venules with IgA deposition and leukocytoclastic vasculitis in is a pathognomonic microscopic feature of Henoch-Schönlein Purpura.
- Skin lesions less than 24 hrs are preferred as the chronic lesion lack the immunoglobulin isotypes essential for the diagnosis of HSP.
- A biopsy from a different skin site is taken for the immunofluorescent studies to confirm the diagnosis.
Renal biopsy
- IgA deposition in the mesangium on immunofluorescence microscopy should be differentiated from the IgA nephropathy.
- Light microscopic features range from isolated mesangial proliferation to severe crescentic glomerulonephritis.
References
- â Yang YH, Yu HH, Chiang BL (2014). “The diagnosis and classification of Henoch-Schönlein purpura: an updated review”. Autoimmun Rev. 13 (4â5): 355â8. doi:10.1016/j.autrev.2014.01.031. PMID 24424188.
- â Trnka P (December 2013). “Henoch-Schönlein purpura in children”. J Paediatr Child Health. 49 (12): 995â1003. doi:10.1111/jpc.12403. PMID 24134307.
- â Rigante D, Castellazzi L, Bosco A, Esposito S (August 2013). “Is there a crossroad between infections, genetics, and Henoch-Schönlein purpura?”. Autoimmun Rev. 12 (10): 1016â21. doi:10.1016/j.autrev.2013.04.003. PMID 23684700.
- â Jennette JC, Falk RJ (November 1997). “Small-vessel vasculitis”. N. Engl. J. Med. 337 (21): 1512â23. doi:10.1056/NEJM199711203372106. PMIDÂ 9366584.
- â Chen JY, Mao JH (February 2015). “Henoch-Schönlein purpura nephritis in children: incidence, pathogenesis and management”. World J Pediatr. 11 (1): 29â34. doi:10.1007/s12519-014-0534-5. PMID 25557596.
- â Kawasaki Y, Ono A, Ohara S, Suzuki Y, Suyama K, Suzuki J, Hosoya M (2013). “Henoch-Schönlein purpura nephritis in childhood: pathogenesis, prognostic factors and treatment”. Fukushima J Med Sci. 59 (1): 15â26. PMID 23842510.
Causes
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
The common causes of Henoch-Schönlein purpura (HSP) are infections, medications, hypersensitivity, vaccinations, genetics etc.
Causes
- Common causes
- Infections–
- Medications
- Hypersensitivity
- Vaccinations– certain vaccines can cause HSP such as Typhoid, HBV, Measles, Yellow fever, and Cholera.
- Rare causes
- In HSP, the antibodies are directed against the blood vessels causing vasculitis, bleeding into the skin leading to a subsequent skin rash.
- Allergic reaction to foods may cause HSP.
- Very rarely HSP can occur in twins and within the family.
References
- â Davin JC, Coppo R (October 2014). “Henoch-Schönlein purpura nephritis in children”. Nat Rev Nephrol. 10 (10): 563â73. doi:10.1038/nrneph.2014.126. PMID 25072122.
- â Micheletti RG, Werth VP (2015). “Small vessel vasculitis of the skin”. Rheum. Dis. Clin. North Am. 41 (1): 21â32, vii. doi:10.1016/j.rdc.2014.09.006. PMIDÂ 25399937.
- â Zhdanova LV, Patrushev LI, Dolgikh VV, Bimbaev AB, KhoÄkova O (2014). “[The contribution of genes polymorphism of thrombophilia in clinical variability of hemorrhagic vasculitis]”. Vestn. Akad. Med. Nauk SSSR (in Russian) (3â4): 61â4. PMIDÂ 25306598. Vancouver style error: initials (help)
- â Rigante D, Castellazzi L, Bosco A, Esposito S (August 2013). “Is there a crossroad between infections, genetics, and Henoch-Schönlein purpura?”. Autoimmun Rev. 12 (10): 1016â21. doi:10.1016/j.autrev.2013.04.003. PMID 23684700.
- â Audemard-Verger A, Pillebout E, Guillevin L, Thervet E, Terrier B (July 2015). “IgA vasculitis (Henoch-Shönlein purpura) in adults: Diagnostic and therapeutic aspects”. Autoimmun Rev. 14 (7): 579â85. doi:10.1016/j.autrev.2015.02.003. PMID 25688001.
- â Pillebout E, Niaudet P (March 2008). “[Henoch-Schönlein purpura]”. Rev Prat (in French). 58 (5): 507â11. PMID 18524107.
Differentiating Henoch-Schönlein purpura from other Diseases

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Henoch-Schönlein purpura should be differentiated from other immune complex mediated small vessel vasculitis such as Anti-glomerular basement membrane disease, Cryoglobulinemic vasculitis, Hepatitis C virus-associated cryoglobulinemic vasculitis, Hypocomplementemic urticarial vasculitis (anti-C1q vasculitis).
Differentiating Henoch-Schönlein Purpura from other Diseases
Henoch-Schönlein purpura should be differentiated from other immune complex mediated small vessel vasculitis such as Anti-glomerular basement membrane disease, Cryoglobulinemic vasculitis, Hepatitis C virus-associated cryoglobulinemic vasculitis, Hypocomplementemic urticarial vasculitis (anti-C1q vasculitis).
Differential Diagnosis
Abbreviations: ABG= Arterial blood gas, ANA= Antinuclear antibody, ANP= Atrial natriuretic peptide, ASO= Antistreptolysin O antibody, BNP= Brain natriuretic peptide, CBC= Complete blood count, COPD= Chronic obstructive pulmonary disease, CRP= C-reactive protein, CT= Computed tomography, CXR= Chest X-ray, DVT= Deep vein thrombosis, ESR= Erythrocyte sedimentation rate, HRCT= High Resolution CT, IgE= Immunoglobulin E, LDH= Lactate dehydrogenase, PCWP= Pulmonary capillary wedge pressure, PCR= Polymerase chain reaction, PFT= Pulmonary function test.
References
- â Vaideeswar P, Deshpande JR (2013). “Pathology of Takayasu arteritis: A brief review”. Ann Pediatr Cardiol. 6 (1): 52â8. doi:10.4103/0974-2069.107235. PMCÂ 3634248. PMIDÂ 23626437.
- â Calvo-Romero JM (2003). “Giant cell arteritis”. Postgrad Med J. 79 (935): 511â5. PMCÂ 1742823. PMIDÂ 13679546.
- â Stafa A, Leonardi M (2008). “Role of neuroradiology in evaluating cerebral aneurysms”. Interv Neuroradiol. 14 Suppl 1: 23â37. doi:10.1177/15910199080140S106. PMCÂ 3328052. PMIDÂ 20557771.
- â Cassiman C, Casteels I, Stalmans P, Legius E, Jacob J (2017). “Optical Coherence Tomography Angiography of Retinal Microvascular Changes Overlying Choroidal Nodules in Neurofibromatosis Type 1”. Case Rep Ophthalmol. 8 (1): 214â220. doi:10.1159/000469702. PMCÂ 5422752. PMIDÂ 28512424.
- â Evans, D G. R (2000). “Neurofibromatosis type 2”. Journal of Medical Genetics. 37 (12): 897â904. doi:10.1136/jmg.37.12.897. ISSNÂ 1468-6244.
- â 6.0 6.1 Plouin PF, Perdu J, La Batide-Alanore A, Boutouyrie P, Gimenez-Roqueplo AP, Jeunemaitre X (2007). “Fibromuscular dysplasia”. Orphanet J Rare Dis. 2: 28. doi:10.1186/1750-1172-2-28. PMCÂ 1899482. PMIDÂ 17555581.
- â Gazit Y, Jacob G, Grahame R (2016). “Ehlers-Danlos Syndrome-Hypermobility Type: A Much Neglected Multisystemic Disorder”. Rambam Maimonides Med J. 7 (4). doi:10.5041/RMMJ.10261. PMCÂ 5101008. PMIDÂ 27824552.
- â Michet CJ, Matteson EL (2008). “Polymyalgia rheumatica”. BMJ. 336 (7647): 765â9. doi:10.1136/bmj.39514.653588.80. PMCÂ 2287267. PMIDÂ 18390527.
- â Baker KR, Rice L (2012). “The amyloidoses: clinical features, diagnosis and treatment”. Methodist Debakey Cardiovasc J. 8 (3): 3â7. PMCÂ 3487569. PMIDÂ 23227278.
- â Howard T, Ahmad K, Swanson JA, Misra S (2014). “Polyarteritis nodosa”. Tech Vasc Interv Radiol. 17 (4): 247â51. doi:10.1053/j.tvir.2014.11.005. PMCÂ 4363102. PMIDÂ 25770638.
- â Sharma A, Sharma K (September 2013). “Hepatotropic viral infection associated systemic vasculitides-hepatitis B virus associated polyarteritis nodosa and hepatitis C virus associated cryoglobulinemic vasculitis”. J Clin Exp Hepatol. 3 (3): 204â12. doi:10.1016/j.jceh.2013.06.001. PMCÂ 4216827. PMIDÂ 25755502.
- â Takahashi K, Oharaseki T, Yokouchi Y (2011). “Pathogenesis of Kawasaki disease”. Clin Exp Immunol. 164 Suppl 1: 20â2. doi:10.1111/j.1365-2249.2011.04361.x. PMCÂ 3095860. PMIDÂ 21447126.
- â Heegaard ED, Brown KE (2002). “Human parvovirus B19”. Clin Microbiol Rev. 15 (3): 485â505. PMCÂ 118081. PMIDÂ 12097253.
- â Basetti S, Hodgson J, Rawson TM, Majeed A (2017). “Scarlet fever: a guide for general practitioners”. London J Prim Care (Abingdon). 9 (5): 77â79. doi:10.1080/17571472.2017.1365677. PMCÂ 5649319. PMIDÂ 29081840.
- â Vostral SL (2011). “Rely and Toxic Shock Syndrome: a technological health crisis”. Yale J Biol Med. 84 (4): 447â59. PMCÂ 3238331. PMIDÂ 22180682.
- â Balfour HH, Dunmire SK, Hogquist KA (2015). “Infectious mononucleosis”. Clin Transl Immunology. 4 (2): e33. doi:10.1038/cti.2015.1. PMCÂ 4346501. PMIDÂ 25774295.
- â Levett PN (April 2001). “Leptospirosis”. Clin. Microbiol. Rev. 14 (2): 296â326. doi:10.1128/CMR.14.2.296-326.2001. PMCÂ 88975. PMIDÂ 11292640.
- â Biesiada G, Czepiel J, LeĆniak MR, Garlicki A, Mach T (2012). “Lyme disease: review”. Arch Med Sci. 8 (6): 978â82. doi:10.5114/aoms.2012.30948. PMCÂ 3542482. PMIDÂ 23319969.
- â White SJ, Boldt KL, Holditch SJ, Poland GA, Jacobson RM (2012). “Measles, mumps, and rubella”. Clin Obstet Gynecol. 55 (2): 550â9. doi:10.1097/GRF.0b013e31824df256. PMCÂ 3334858. PMIDÂ 22510638.
- â Walker DH (1989). “Rocky Mountain spotted fever: a disease in need of microbiological concern”. Clin Microbiol Rev. 2 (3): 227â40. PMCÂ 358117. PMIDÂ 2504480.
- â Mishra AK, Yadav P, Mishra A (2016). “A Systemic Review on Staphylococcal Scalded Skin Syndrome (SSSS): A Rare and Critical Disease of Neonates”. Open Microbiol J. 10: 150â9. doi:10.2174/1874285801610010150. PMCÂ 5012080. PMIDÂ 27651848.
- â Hoetzenecker W, Mehra T, Saulite I, Glatz M, Schmid-Grendelmeier P, Guenova E; et al. (2016). “Toxic epidermal necrolysis”. F1000Res. 5. doi:10.12688/f1000research.7574.1. PMCÂ 4879934. PMIDÂ 27239294.
- â MacGowan SW, Sidhu P, Aherne T, Luke D, Wood AE, Neligan MC, McGovern E (June 1993). “Atrial myxoma: national incidence, diagnosis and surgical management”. Ir J Med Sci. 162 (6): 223â6. PMIDÂ 8407260.
- â Avci G, Akoz T, Gul AE (2009). “Cutaneous cholesterol embolization”. J Dermatol Case Rep. 3 (2): 27â9. doi:10.3315/jdcr.2009.1031. PMCÂ 3157794. PMIDÂ 21886725.
- â Chao, Christine (2009). “Segmental Arterial Mediolysis”. Seminars in Interventional Radiology. 26 (03): 224â232. doi:10.1055/s-0029-1225666. ISSNÂ 0739-9529.
- â Chaturvedi S, McCrae KR (2015). “The antiphospholipid syndrome: still an enigma”. Hematology Am Soc Hematol Educ Program. 2015: 53â60. doi:10.1182/asheducation-2015.1.53. PMCÂ 4877624. PMIDÂ 26637701.
- â Espinosa M, Gottlieb BS (July 2012). “Juvenile idiopathic arthritis”. Pediatr Rev. 33 (7): 303â13. doi:10.1542/pir.33-7-303. PMIDÂ 22753788.
- â Chung SA, Seo P (2010). “Microscopic polyangiitis”. Rheum Dis Clin North Am. 36 (3): 545â58. doi:10.1016/j.rdc.2010.04.003. PMCÂ 2917831. PMIDÂ 20688249.
- â Kubaisi B, Abu Samra K, Foster CS (2016). “Granulomatosis with polyangiitis (Wegener’s disease): An updated review of ocular disease manifestations”. Intractable Rare Dis Res. 5 (2): 61â9. doi:10.5582/irdr.2016.01014. PMCÂ 4869584. PMIDÂ 27195187.
- â Keogh KA, Specks U (April 2006). “Churg-Strauss syndrome”. Semin Respir Crit Care Med. 27 (2): 148â57. doi:10.1055/s-2006-939518. PMIDÂ 16612766.
- â Keasberry J, Frazier J, Isbel NM, Van Eps CL, Oliver K, Mudge DW (2013). “Hydralazine-induced anti-neutrophil cytoplasmic antibody-positive renal vasculitis presenting with a vasculitic syndrome, acute nephritis and a puzzling skin rash: a case report”. J Med Case Rep. 7: 20. doi:10.1186/1752-1947-7-20. PMCÂ 3565908. PMIDÂ 23316942.
- â McAdoo SP, Pusey CD (July 2017). “Anti-Glomerular Basement Membrane Disease”. Clin J Am Soc Nephrol. 12 (7): 1162â1172. doi:10.2215/CJN.01380217. PMIDÂ 28515156.
- â Ferri C, Mascia MT (January 2006). “Cryoglobulinemic vasculitis”. Curr Opin Rheumatol. 18 (1): 54â63. PMIDÂ 16344620.
- â Guo QY, Wu M, Wang YW, Sun GD (2017). “Hepatitis C virus-associated cryoglobulinemia with membrano-proliferative glomerulonephritis treated with prednisolone and interferon: A case report”. Exp Ther Med. 14 (2): 1395â1398. doi:10.3892/etm.2017.4671. PMCÂ 5525644. PMIDÂ 28810602.
- â Farhadian JA, Castilla C, Shvartsbeyn M, Meehan SA, Neimann A, Pomeranz MK (December 2015). “IgA vasculitis (Henoch-Schönlein purpura)”. Dermatol. Online J. 21 (12). PMID 26990342.
- â Buck A, Christensen J, McCarty M (2012). “Hypocomplementemic urticarial vasculitis syndrome: a case report and literature review”. J Clin Aesthet Dermatol. 5 (1): 36â46. PMCÂ 3277093. PMIDÂ 22328958.
- â Sise MJ (February 2014). “Acute mesenteric ischemia”. Surg. Clin. North Am. 94 (1): 165â81. doi:10.1016/j.suc.2013.10.012. PMIDÂ 24267504.
- â McDonald JR (2009). “Acute infective endocarditis”. Infect Dis Clin North Am. 23 (3): 643â64. doi:10.1016/j.idc.2009.04.013. PMCÂ 2726828. PMIDÂ 19665088.
- â Einhorn J, Levis JT (2015). “Dermatologic Diagnosis: Leukocytoclastic Vasculitis”. Perm J. 19 (3): 77â8. doi:10.7812/TPP/15-001. PMCÂ 4500485. PMIDÂ 26176572.
- â Margo CE, Goldman DR (2008). “Langerhans cell histiocytosis”. Surv Ophthalmol. 53 (4): 332â58. doi:10.1016/j.survophthal.2008.04.007. PMIDÂ 18572052.
- â Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA (2008). “Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship”. Mayo Clin Proc. 83 (5): 584â94. doi:10.4065/83.5.584. PMCÂ 2718421. PMIDÂ 18452692.
- â Jackman DM, Johnson BE (2005). “Small-cell lung cancer”. Lancet. 366 (9494): 1385â96. doi:10.1016/S0140-6736(05)67569-1. PMIDÂ 16226617.
- â Parambil JG, Savci CD, Tazelaar HD, Ryu JH (April 2005). “Causes and presenting features of pulmonary infarctions in 43 cases identified by surgical lung biopsy”. Chest. 127 (4): 1178â83. doi:10.1378/chest.127.4.1178. PMIDÂ 15821192.
- â VanDeVoorde RG (January 2015). “Acute poststreptococcal glomerulonephritis: the most common acute glomerulonephritis”. Pediatr Rev. 36 (1): 3â12, quiz 13. doi:10.1542/pir.36-1-3. PMIDÂ 25554106.
- â Corrigan JJ, Boineau FG (November 2001). “Hemolytic-uremic syndrome”. Pediatr Rev. 22 (11): 365â9. PMIDÂ 11691946.
- â Byrd JC, Stilgenbauer S, Flinn IW (2004). “Chronic lymphocytic leukemia”. Hematology Am Soc Hematol Educ Program: 163â83. doi:10.1182/asheducation-2004.1.163. PMIDÂ 15561682.
- â Michels TC, Petersen KE (March 2017). “Multiple Myeloma: Diagnosis and Treatment”. Am Fam Physician. 95 (6): 373â383. PMIDÂ 28318212.
- â Klion A (2009). “Hypereosinophilic syndrome: current approach to diagnosis and treatment”. Annu. Rev. Med. 60: 293â306. doi:10.1146/annurev.med.60.062107.090340. PMIDÂ 19630574.
- â Shankland KR, Armitage JO, Hancock BW (September 2012). “Non-Hodgkin lymphoma”. Lancet. 380 (9844): 848â57. doi:10.1016/S0140-6736(12)60605-9. PMIDÂ 22835603.
- â Lin RY (January 1986). “Serum sickness syndrome”. Am Fam Physician. 33 (1): 157â62. PMIDÂ 2867672.
- â Venugopal A (2014). “Disseminated intravascular coagulation”. Indian J Anaesth. 58 (5): 603â8. doi:10.4103/0019-5049.144666. PMCÂ 4260307. PMIDÂ 25535423.
- â Nomura S (2016). “Advances in Diagnosis and Treatments for Immune Thrombocytopenia”. Clin Med Insights Blood Disord. 9: 15â22. doi:10.4137/CMBD.S39643. PMCÂ 4948655. PMIDÂ 27441004.
- â Chiarchiaro J, Chen BB, Gibson KF (2016). “New molecular targets for the treatment of sarcoidosis”. Curr Opin Pulm Med. 22 (5): 515â21. doi:10.1097/MCP.0000000000000304. PMCÂ 5152532. PMIDÂ 27454074.
- â Murdoch DR (January 2003). “Diagnosis of Legionella infection”. Clin. Infect. Dis. 36 (1): 64â9. doi:10.1086/345529. PMIDÂ 12491204.
- â Tsokos, George C. (2011). “Systemic Lupus Erythematosus”. New England Journal of Medicine. 365 (22): 2110â2121. doi:10.1056/NEJMra1100359. ISSNÂ 0028-4793.
- â Scott JT (1991). “The gold standard in rheumatoid arthritis”. J R Soc Med. 84 (9): 513â4. PMCÂ 1293405. PMIDÂ 1682491.
- â Emmungil H, Aydın SZ (2015). “Relapsing polychondritis”. Eur J Rheumatol. 2 (4): 155â159. doi:10.5152/eurjrheum.2015.0036. PMC 5047229. PMID 27708954.
- â Yazici H, Fresko I, Yurdakul S (March 2007). “Behçet’s syndrome: disease manifestations, management, and advances in treatment”. Nat Clin Pract Rheumatol. 3 (3): 148â55. doi:10.1038/ncprheum0436. PMID 17334337.
- â Iliescu DA, Timaru CM, Batras M, De Simone A, Stefan C (2015). “COGAN’S SYNDROME”. Rom J Ophthalmol. 59 (1): 6â13. PMCÂ 5729811. PMIDÂ 27373108.
- â Wehkamp J, Götz M, Herrlinger K, Steurer W, Stange EF (2016). “Inflammatory Bowel Disease”. Dtsch Arztebl Int. 113 (5): 72â82. doi:10.3238/arztebl.2016.0072. PMC 4782273. PMID 26900160.
- â Dutly F, Altwegg M (2001). “Whipple’s disease and “Tropheryma whippelii““. Clin Microbiol Rev. 14 (3): 561â83. doi:10.1128/CMR.14.3.561-583.2001. PMCÂ 88990. PMIDÂ 11432814.
- â Stefanski AL, Tomiak C, Pleyer U, Dietrich T, Burmester GR, Dörner T (2017). “The Diagnosis and Treatment of Sjögren’s Syndrome”. Dtsch Arztebl Int. 114 (20): 354â361. doi:10.3238/arztebl.2017.0354. PMC 5471601. PMID 28610655.
- â Benseler SM, Silverman E, Aviv RI, Schneider R, Armstrong D, Tyrrell PN, deVeber G (April 2006). “Primary central nervous system vasculitis in children”. Arthritis Rheum. 54 (4): 1291â7. doi:10.1002/art.21766. PMIDÂ 16575852.
- â LatgĂ© JP (1999). “Aspergillus fumigatus and aspergillosis”. Clin Microbiol Rev. 12 (2): 310â50. PMC 88920. PMID 10194462.
- â GuimarĂŁes AJ, Nosanchuk JD, ZancopĂ©-Oliveira RM (2006). “DIAGNOSIS OF HISTOPLASMOSIS”. Braz J Microbiol. 37 (1): 1â13. doi:10.1590/S1517-83822006000100001. PMC 2863343. PMID 20445761.
- â Sköldenberg B (1996). “Herpes simplex encephalitis”. Scand J Infect Dis Suppl. 100: 8â13. PMID 9163027.
- â Uzan J, Carbonnel M, Piconne O, Asmar R, Ayoubi JM (2011). “Pre-eclampsia: pathophysiology, diagnosis, and management”. Vasc Health Risk Manag. 7: 467â74. doi:10.2147/VHRM.S20181. PMCÂ 3148420. PMIDÂ 21822394.
Epidemiology and demographics
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
The incidence of HSP is approximately 6-20 cases per 100,000 individuals. The prevalence of HSP is more in children of 4-6 years age group. HSP usually affects Caucasians than any other ethnic groups. Males are more commonly affected by HSP than females. The Male to female ratio is approximately 1.5-2:1.
Epidemiology and demgraphics
Epidemiology and demgraphics of HSP:[1][2]
Incidence
- The incidence of HSP is approximately 6-20 cases per 100,000 individuals.
Age
- The prevalence of HSP is more in children of 4-6 years age group.
Race
- HSP usually affects Caucasians than any other ethnic groups.
Gender
- Males are more commonly affected by HSP than females. The Male to female ratio is approximately 1.5-2:1.
References
- â Kang Y, Park JS, Ha YJ, Kang MI, Park HJ, Lee SW, Lee SK, Park YB (February 2014). “Differences in clinical manifestations and outcomes between adult and child patients with Henoch-Schönlein purpura”. J. Korean Med. Sci. 29 (2): 198â203. doi:10.3346/jkms.2014.29.2.198. PMC 3923997. PMID 24550645.
- â Schmoldt A, Benthe HF, Haberland G, Sinelnikova EM, Dvoretskova TV, Kagan ZS, Horty JF, Geering K, Becker M, Beglinger R, Stauffer UG (September 1975). “Digitoxin metabolism by rat liver microsomes”. Biochem. Pharmacol. 24 (17): 1639â41. PMIDÂ 10.
Risk Factors
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Henoch-Schönlein purpura (HSP) is associated with following risk factors it’s most common in children of 2 to 6 years, involves young boys more than girls, Asian and white race, spring, fall and winter months, Group A streptococci, Mycoplasma, Epstein-Barr virus infections, and environmental exposure of allergens, organophosphates, cold temperature.
Risk Factors
The risk factors of the Henoch-Schönlein purpura are as follows:[1][2][3][4][5]
- Age– Most common in children of 2 to 6 years.
- Sex– Males more than females.
- Race– Asian and white.
- Season– Spring, fall and winter months.
- Infections– Group A streptococci, Mycoplasma, Epstein-Barr virus.
- Environmental – allergens, organophosphates, cold temperature.
References
- â Park SJ, Suh JS, Lee JH, Lee JW, Kim SH, Han KH, Shin JI (December 2013). “Advances in our understanding of the pathogenesis of Henoch-Schönlein purpura and the implications for improving its diagnosis”. Expert Rev Clin Immunol. 9 (12): 1223â38. doi:10.1586/1744666X.2013.850028. PMID 24215411.
- â Saulsbury FT (January 2001). “Henoch-Schönlein purpura”. Curr Opin Rheumatol. 13 (1): 35â40. PMID 11148713.
- â Bucher B, Fiore E, Bernasconi M, Blumberg D, Garzoni L, Rizzi M, Bianchetti MG (May 2008). “[Childhood Henoch-Schönlein syndrome–common and uncommon features, complications, Finkelstein-Seidlmayer variant and management]”. Ther Umsch (in German). 65 (5): 269â77. doi:10.1024/0040-5930.65.5.269. PMID 18622931.
- â Nunnelee JD (March 2000). “Henoch-Schönlein purpura: a review of the literature”. Clin Excell Nurse Pract. 4 (2): 72â5. PMID 11075047.
- â Patrignelli R, Sheikh SH, Shaw-Stiffel TA (May 1995). “Henoch-Schönlein purpura. A multisystem disease also seen in adults”. Postgrad Med. 97 (5): 123â4, 127, 131â4. PMID 7753737.
Natural History, Complications and Prognosis
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Henoch-Schönlein purpura is a self-limiting illness in the majority of patients but can rarely lead to complications such as proteinuria, End Stage Renal Disease, myocardial infarction, pulmonary hemorrhage, pleural effusion, intussusception, orchitis, GI bleeding, bowel infarction, seizures, neuropathies. The prognosis is usually good but rarely its worse in adults with renal involvement.
Natural History
- The natural history of HSP is as follows:[1][2][3][4][5][6][7]
- Henoch-Schönlein purpura is a self-limiting illness in the majority of patients.
- The abdominal and joint pain may be debilitating, and steroids have been used with some success in relieving the abdominal pain.
- The vasculitis of the gastrointestinal tract causes significant blood loss and occasionally leading to bowel ischemia, which may necessitate bowel resection.
- There is no clear evidence that remedy alters the progression of the HSP, however, the significant long-term morbidity related to the renal disease that has led to trials of steroids and other immunosuppressive drugs.
Complications
The complications of the HSP are as follows:[1][2][3][4][5][6][7]
- Renal involvement- Proteinuria, End Stage Renal Disease in 1% of patients.
- Other complications
- Myocardial infarction
- Pulmonary hemorrhage
- Pleural effusion
- Intussusception of both small and large intestines
- Orchitis
- GI bleeding
- Bowel infarction
- Seizures
- Neuropathies.
Prognosis
- The prognosis of the HSP:[8][2][9][10][11][12]
- Henoch-Schönlein purpura is an acute self-limited illness, can seldom cause complications.
- Initial attacks of HSP can last for several months. One in every four patients will have one or more recurrences.
- HSP is more benign, short course and less recurrent in children less than three years.
- CKD can progress more than 10 years after the initial HSP attack.
- The long-term prognosis of HSP depends on the extent of the kidney involvement.
- Renal involvement of more common and the prognosis is worst in adults with HSP than the children.
References
- â 1.0 1.1 Scheller F, JĂ€nchen M, Lampe J, PrĂŒmke HJ, Blanck J, Palecek E, Chow YW, Pietranico R, Mukerji A, Reynolds CH (November 1975). “Studies on electron transfer between mercury electrode and hemoprotein”. Biochim. Biophys. Acta. 412 (1): 157â67. PMIDÂ 79.
- â 2.0 2.1 2.2 Trnka P (December 2013). “Henoch-Schönlein purpura in children”. J Paediatr Child Health. 49 (12): 995â1003. doi:10.1111/jpc.12403. PMID 24134307.
- â 3.0 3.1 Kanaan N, Mourad G, Thervet E, Peeters P, Hourmant M, Vanrenterghem Y, De Meyer M, Mourad M, MarĂ©chal C, Goffin E, Pirson Y (July 2011). “Recurrence and graft loss after kidney transplantation for henoch-schonlein purpura nephritis: a multicenter analysis”. Clin J Am Soc Nephrol. 6 (7): 1768â72. doi:10.2215/CJN.00520111. PMID 21734091.
- â 4.0 4.1 Samuel JP, Bell CS, Molony DA, Braun MC (August 2011). “Long-term outcome of renal transplantation patients with Henoch-Schonlein purpura”. Clin J Am Soc Nephrol. 6 (8): 2034â40. doi:10.2215/CJN.01410211. PMCÂ 3359547. PMIDÂ 21700827.
- â 5.0 5.1 Poterucha TJ, Wetter DA, Grande JP, Gibson LE, Camilleri MJ, Lohse CM (July 2014). “A retrospective comparison of skin and renal direct immunofluorescence findings in patients with glomerulonephritis in adult Henoch-Schönlein purpura”. J. Cutan. Pathol. 41 (7): 582â7. PMID 25097917.
- â 6.0 6.1 D’Souza S, Hageman JR, Patel P, Littlejohn E (March 2014). “Henoch-Schöenlein purpura and diabetes mellitus in a 9-year-old African-American male”. Pediatr Ann. 43 (3): e61â4. doi:10.3928/00904481-20140221-09. PMID 24605861.
- â 7.0 7.1 Pohl M (February 2015). “Henoch-Schönlein purpura nephritis”. Pediatr. Nephrol. 30 (2): 245â52. doi:10.1007/s00467-014-2815-6. PMID 24733586.
- â Pillebout E, Verine J (June 2014). “[Henoch-Schönlein purpura in the adult]”. Rev Med Interne (in French). 35 (6): 372â81. doi:10.1016/j.revmed.2013.12.004. PMID 24657040.
- â Davin JC, Coppo R (October 2014). “Henoch-Schönlein purpura nephritis in children”. Nat Rev Nephrol. 10 (10): 563â73. doi:10.1038/nrneph.2014.126. PMID 25072122.
- â Kawasaki Y, Ono A, Ohara S, Suzuki Y, Suyama K, Suzuki J, Hosoya M (2013). “Henoch-Schönlein purpura nephritis in childhood: pathogenesis, prognostic factors and treatment”. Fukushima J Med Sci. 59 (1): 15â26. PMID 23842510.
- â Kang Y, Park JS, Ha YJ, Kang MI, Park HJ, Lee SW, Lee SK, Park YB (February 2014). “Differences in clinical manifestations and outcomes between adult and child patients with Henoch-Schönlein purpura”. J. Korean Med. Sci. 29 (2): 198â203. doi:10.3346/jkms.2014.29.2.198. PMC 3923997. PMID 24550645.
- â Davin JC (March 2011). “Henoch-Schonlein purpura nephritis: pathophysiology, treatment, and future strategy”. Clin J Am Soc Nephrol. 6 (3): 679â89. doi:10.2215/CJN.06710810. PMIDÂ 21393485.
Diagnosis
Diagnosis
History and Symptoms | Physical Examination | Laboratory Findings | Electrocardiogram | Chest X Ray | CT | MRI | Echocardiography or Ultrasound | Other Imaging Findings | Other Diagnostic Studies
Looking for the patient version?
© 2026 MyEClinic â IFTM Institut fĂŒr Telematik in der Medizin GmbH
